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SUPPLEMENTAL DATA 
Clinical history 
The propositus of Pedigree 1’s bleeding symptoms comprised prolonged bleeding after a 
previous mastectomy and axillary node clearance procedure for breast carcinoma that 
required blood transfusion. There was prolonged bleeding after extraction of one wisdom 
tooth, but no other pathological bleeding symptoms. Uterine dilatation and curettage, 
joint injection, three other wisdom tooth extractions, mole removal and a spontaneous 
vaginal delivery were not complicated by excessive bleeding.  
The hysterectomy of the propositus of Pedigree 2 was complicated by post-operative 
bleeding for which she received a blood transfusion. Following two dental extractions, 
she had prolonged bleeding, which necessitated suturing to achieve haemostasis. She also 
reported intermittent heavy blood loss for up to 8 weeks following two first trimester 
miscarriages and after her first delivery. However, she did not require iron therapy or 
blood products. She did undergo a laparoscopic cholecystectomy, minor ophthalmic 
surgery and two spontaneous vaginal deliveries with no excessive bleeding.  
Case 2-III-7 experienced bleeding for 3 days following a molar extraction, which 
eventually ceased with no intervention. She also suffered with longstanding menorrhagia 
and bled following a spontaneous vaginal delivery requiring iron replacement therapy.	  
 
Supplemental Methods 
Materials. ENU, ADP, thrombin, Dimethyl sulfoxide (DMSO), propidium iodide 
(Sigma-Aldrich) and CVX (Enzo Life Sciences Inc.) were purchased. The enhanced 
chemiluminescence system was from Merck Millipore, the protease inhibitor cocktail, 
Complete, was from Roche. Rhodamine phalloidine and 4%-12% Bis-Tris gels 
(NuPAGE) were from Invitrogen Life technologies, and calibration beads 3.5–4.0 µm 
were from Spherotech Inc. X488 was obtained from Emfret Analytics. Anesthetic drugs 
xylazine (Rompun) and ketamine (Imalgene 1000) were from Bayer and Mérial Inc., 
respectively. Antibodies used for immunoblotting and immunofluorescence microscopy 
included: Rabbit anti-TPM4 exon 9d (#AB544) and mouse anti-TPM1/2 (15D12.2) from 
EMD Millipore; mouse anti-NMM-IIa (#ab55456), rabbit anti-ROCK (#ab71598) and 
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rabbit anti-TPM4 (EPR13317) from Abcam, rabbit anti-P-cofilin (Ser3, #3311) and rabbit 
anti-P-NMM-IIa (Ser1943, #5026) from Cell Signalling, mouse anti-RhoA (#ARH03) 
and rabbit anti-cofilin (#ACFL02) (Cytoskeleton), rabbit anti-Actinin1 (#HPA006035) 
from Sigma, rabbit anti-Filamin A (#PA5-29598 Thermo Scientific), and anti-actin-HRP 
(#sc-47778 Santa Cruz Biotechnology). Mouse anti-TPM4 exon 1b (clone #44), anti-
TPM4 WD4/9d and anti-TPM3 (2G10.2) antibodies were generated as described (1). 
Antibodies used for flow cytometry to determine platelet activation and platelet surface 
receptor expression: Fluorescently conjugated GPIbα (Xia.G5), GPIX (Xia. B4), GPVI 
(JAQ1) antibodies, as well as the antibody directed against active integrin 
GPIIbIIIa/αIIbβ3 (JON/A) were obtained from Emfret Analytics.  
Generation of BM chimeras. Lethally irradiated adult CD45.1 congenic Balb/c mice 
were transplanted with whole bone marrow of Tpm4Plt53/Plt53 or Tpm4+/+ mice (4×106 
cells per recipient). Seven weeks after transplant, blood cell counts were measured.  
Platelet transmission electron microscopy (TEM). Human: Human platelets were 
incubated for 20 minutes at 37°C before fixation with 0.2% glutaraldehyde. After 
incubation for 1hr at room temperature, cells were washed twice with saline solution 
before overnight fixation at 4ºC with 0.2% glutaraldehyde in 0.1 M sodium cacodylate 
buffer. This was followed by immersion in 2% formaldehyde (made from 
paraformaldehyde) and 2% vacuum distilled glutaraldehyde, containing 2 mM CaCl2 in 
0.05 M sodium cacodylate buffer pH 7.4 at 4ºC for 8 hours. Platelets were washed 5 
times for 3 minutes in cold cacodylate buffer containing 2 mM CaCl2 before incubation 
for 18 hours at 4ºC in 1% osmium ferricyanide followed by 5 washes with deionized 
water. Samples were then incubated for 30 minutes at room temperature in 1% 
thiocarbohydrazide followed by 5 washes with deionized water. Samples were incubated 
in 1% uranyl acetate in 0.05 M maleate buffer pH 5.5 for 48 hours at 4ºC before washing 
5 times for 3 minutes in deionized water at room temperature. Platelets were dehydrated 
through 2 times each of 50%, 70%, 90% and 100% ethanol, followed by twice each in 
series of dry ethanol, dry acetone and dry acetonitrile, before being infiltrated with 
Quetol 651 epoxy resin over 5 days. The resin was cured for 48 hours at 65ºC before thin 
sections were prepared with a Leica Ultracut S, mounted on 200 mesh copper grids and 
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viewed with a Tecnia G2 operated at 200kV. Mouse: For visualization of the 
ultrastructure of mouse platelets, washed platelets were fixed with 2.5% glutaraldehyde 
in 0.1 M cacodylate buffer (pH 7.2). Samples were processed for TEM as described 
previously (2).  
Megakaryocyte culture. Human: Cord blood was obtained after informed consent under 
a protocol approved by the National Research Ethics Service (07/MRE05/44). CD34-
positive cells (>90%) isolated by magnetic cell sorting (Miltenyi Biotec), were seeded at 
1x105 cells/ml in CellGro SCGM medium (CellGenix) with 100 ng/ml human TPO 
(CellGenix) and 10 ng/ml IL-1b (CellGenix) and incubated for 10 days. On day 3 of 
culture, cells were transduced with lentivirus at 50 TU/cell before puromycin selection 
was added (day 6). CD41/CD42 expression was evaluated on day 10 before lysates were 
prepared for RNA and protein expression analysis. Flow cytometry was performed on a 
CyAn ADP 9 color (Beckman Coulter) using the following antibodies CD34PE (clone 
581; Beckman Coulter), CD41aAPC (clone HIP8; BD Pharmingen), CD42aPE (clone 
ALMA.16; BD Pharmingen). For analysis of proplatelet formation, megakaryocyte 
maturity was verified by CD41/42 staining on day 8 of culture before cells were seeded at 
7.5x104 cells per well on 12-well chamber slides (Ibidi) pre-coated with fibrinogen (200 
µg/ml, Enzyme Research Laboratories). After 48 hours cells were fixed with 1% 
formaldehyde and stained for TPM4 (rabbit polyclonal, #AB5449, Millipore), β-tubulin 
(#32-2588, Molecular Probes) and actin (phalloidin #R415, Molecular Probes), nuclei 
were counter-stained with DAPI (Fluoroshield, Sigma) and visualized and quantified 
using confocal microscopy (Leica SP5). Mouse: Fetal livers were removed at embryonic 
day (E) 13.5 and transferred into Dulbecco’s modified Eagle’s (DME) medium (high 
glucose version) with 10% fetal calf serum (FCS) (Gibco). Single cell suspensions were 
cultured for 3 days at 5 x 105 cells mL-1 in serum-free medium (SFM) (3) supplemented 
with 100 ng mL-1 murine thrombopoietin (WEHI) at 37°C, 5% CO2, and mature 
megakaryocytes purified using a BSA gradient as described (4). On day 4, the percentage 
of proplatelet-forming megakaryocytes was determined using a light microscope. Time 
lapse video microscopy of proplatelet formation: Day 3 fetal liver megakaryocytes were 
enriched as detailed in the proplatelet formation assay and transferred to optically 
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transparent ibiTreat tissue culture treated sterile µ-slide 8-well plates (Ibidi). Experiments 
were performed using a Biostation IM-Q live cell time lapse imaging system (Nikon) 
equipped with a Nikon DS-Qil Digital Monochrome camera. Time-lapse images were 
acquired for 24 h using a 40×/0.8 objective with a 0.5x tube lense and processed using 
Image J software. Immunofluorescence microscopy: Day 4 megakaryocytes were spun 
onto glass slides, fixed using 4% paraformaldehyde, permeabilized with Triton X-100 
and stained with the indicated antibodies. F-actin was visualized using phalloidin 
rhodamine and nuclei were stained with DAPI. Cells were analysed using a Zeiss LSM 
780 confocal microscope equipped with ZEN software using a 40x/1.4 oil objective. The 
proplatelet tip diameter was measured using ImageJ software. 
Determination of mouse megakaryocyte ploidy. Bone marrow was harvested from 
femora of 8- to 10-week-old mice into 1 mL of CATCH medium and megakaryocyte 
ploidy was studied by staining with CD41-FITC mAb and propidium iodide, as described 
(2).  
Thrombus formation on collagen under flow. Mouse: Rectangular cover slips (24 × 60 
mm) were coated with 200 µg/ml fibrillar type I collagen (Nycomed) and blocked with 
1% BSA. Heparinized whole blood was labeled with a DyLight 488–conjugated anti-
GPIX Ig derivative (0.2 µg/ml) and perfused over collagen-coated coverslips through a 
transparent flow chamber at a shear rate of 1,000 s–1 as previously described (5). 
Brightfield and fluorescence images were obtained from at least 7 different collagen-
containing microscopic fields for each sample using a Zeiss Axiovert 200 inverted 
microscope (×40 objective; Carl Zeiss) and analysed off-line using Metavue software 
(Visitron). Human: Heparinised blood was pumped through a perfusion chamber 
containing collagen. Briefly, cover slips were locally coated with Horm collagen spots 
(50 µg/mL, Nycomed Linz Austria) and then used to assemble a flow chamber placed 
under a fluorescent microscope (EVOS system, Advanced Microscopy Group). The 
blood was then perfused for 3.5 min, followed by the perfusion of P-Selectin antibody 
(clone Thromb/6, NHSBT-Filton) for 2 min and a final wash step with Tyrode-Hepes 
buffer (supplemented with 3.3% BSA, 3.3% Glucose and 4% of 1M MgCl2) for 3 
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additional min. Solutions were perfused at 7.2 mL/h and 1,600 s-1. Thrombi formation on 
collagen spots was recorded and analysed using ImageJ.  
Measurement of platelet F-actin content. Washed mouse platelets (0.02x106/µL) were 
either left unstimulated or were stimulated with 1 U/mL thrombin for 2 minutes (37°C). 
After fixation with 0.55 volume of 10% paraformaldehyde in PBS (10 min) and 
permeabilization with 0.1 volume 1% Triton X-100 platelets were incubated with 10 µM 
phalloidin-FITC for 30 minutes and analysed on a FACSCalibur. 
SDS-PAGE and Western blot analysis. Tpm4Plt53 mutant mice: Mouse platelets and 
megakaryocytes were lysed in NP40 lysis buffer. Proteins were separated on 4-12% Bis-
Tris gels (NuPAGE; Invitrogen) under reducing conditions, transferred onto Millipore 
PDVF membranes, and immunoblotted with various antibodies (see above), followed by 
incubation with secondary HRP-conjugated antibodies and ECL (GE 
Healthcare/Amersham, Pittsburgh, PA, USA). Densitometry analyses were carried out 
using Image J software. Tpm4.2 knockout mice: Protein was extracted from mouse tail 
tips in RIPA buffer and analysed by SDS-PAGE and Western blotting as described 
previously (1) Protein concentration was estimated using Precision Red (Cytoskeleton, 
Inc). Equal amounts of protein (25 µg) were resolved on a 12.5% SDS-PAGE gel before 
electro-transfer to PVDF membranes. Non-specific binding was blocked with blocking 
buffer 1% BSA in TBST (100 mM Tris-Cl, pH 7.5. 150 mM NaCl with 0.05% Tween 
20). TPM4.2 was recognised using an affinity purified δ/9d rabbit polyclonal antibody 
(1:500 in blocking buffer) and secondary antibody donkey anti rabbit Ig-conjugated 
horseradish peroxidase (Jackson Immuno Research Laboratories, Suffolk, UK) (1:10,000 
in blocking buffer). Primary antibody was incubated overnight followed by secondary for 
2 h with 4 x 15 min washes. Blots were developed with the Western Lightning 
Chemiluminescence Reagent (Perkin Elmer Life Sciences; Boston, MA) and exposed to 
x-ray film. Equal protein loading was examined by staining the protein gel blots with 
0.1% (w/v) Coomassie blue R350, 20% (v/v) methanol and 10% (v/v acetic acid). 
Western blots were scanned on a Biorad Gel doc imaging system and quantified using 
ImageJ software. Human: Platelets and megakaryocytes were lysed in RIPA buffer 
(150mM NaCl, 50mM Tris-HCl pH 8, 0.5% sodium deoxycholate, 0.1% SDS, 1% NP40) 
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containing protease inhibitors (complete EDTA-free protease inhibitor cocktail tablets 
Roche). Total cell lysates (5 µg of protein per lane) were separated using NuPage 4-12% 
Bis-Tris gel electrophoresis and transferred to polyvinylidenedifluoride (PVDF) 
membrane Immobilon-FL (Millipore) by electroblotting. Immunoblots were then probed 
with primary antibodies to GAPDH (14C10 Cell Signaling Technology) and β-actin 
(A5441 Sigma). TPM4.2 was recognised using an affinity purified δ/9d rabbit polyclonal 
antibody. Bands were visualized using ECL anti-rabbit IgG HRP or ECL anti-mouse IgG 
HRP (GE Healthcare) and ECL Clarity reagents (Bio-Rad), according to the 
manufacturer's instructions. 
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Supplemental Table.  
 
 
 
 
Determination of levels of platelet surface receptors in Tpm4+/+, Tpm4Plt53/+ and 
Tpm4Plt53/Plt53 platelets by flow cytometry (n=4). Values represent mean fluorescence 
intensities. Significances compared to the control are depicted. Unpaired 2-tailed students 
t test with Bonferroni correction for multiple comparisons. *P < 0.05; ***P < 0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Receptor +/+ Plt53/+ Plt53/Plt53 
CD41 326 ± 23 380 ± 36 (NS) 447 ± 18 (***) 
GPIb 54 ± 5 58 ± 4 (NS) 76 ± 7 (*) 
GPIX 36 ± 12 38 ± 4 (NS) 45 ± 5 (*) 
GPVI 103 ± 5 108 ± 14 (NS) 141 ± 5 (*) 
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Supplemental Figure 1. (A) RNA sequencing data of human blood progenitor 
populations illustrating that human megakaryocytes express TPM1, 3 and 4, and low 
levels of TPM2 (1). (B,C) Sanger sequencing traces showing co-segregation of the 
observed variants with macrothrombocytopenia in (B) Pedigree 1 and (C) Pedigree 2. (D) 
Left: Platelet TPM4 RNA levels measured by RT-PCR using GAPDH as housekeeping 
gene showing TPM4 RNA levels are reduced in carriers of the mutation (2-II-3, 2-III-5 
and 2-III-7) to 46-63% relative to controls but not in the unaffected family member (2-
III-6). Graph depicts representative data from a total of n=3 measurements from 1 
sample. Right: Platelet TPM4 protein levels measured by Western blot normalised to β-
actin. Affected cases show TPM4 levels between 40-95% compared to controls.  
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Supplemental Figure 2. (A) Western blot of mouse wild-type platelets using two 
different anti-TPM4 antibodies. Left: mouse monoclonal antibody clone 3E5H10 (2). 
Right: rabbit monoclonal antibody #ab181156 (Abcam). β-actin was used as loading 
control. (B) The Plt53 phenotype is intrinsic to the haematopoietic system: 
macrothrombocytopenia in lethally irradiated wild-type mice transplanted with whole 
bone marrow of Tpm4Plt53/Plt53 mice. Unpaired 2-tailed Student’s t test. ***P < 0.001. 
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Supplemental Figure 3. (A-C) Generation of Tpm4.2 knockout mice. (A) Genomic 
sequence of Tpm4 exon 1b (3). Intronic sequence in lower case, exon in upper case. 
Guide sequences are underlined with the PAM sites in bold. Cut sites are indicated by / 
and the ATG start codon is boxed. (B) PCR based genotype determination of knockout 
(223 bp) and wild-type alleles (317 bp). (C) Left: Western blot of TPM4.2 protein 
expression in Tpm4.2 wild-type (+/+), heterozygous (+/-), and homozygous (-/-) 
knockout mice. Equal protein loading is demonstrated by the Coomassie stained 
membrane. Right: Densitometry analysis. n=4 independent experiments. (D) Platelet 
count and size in Tpm4Plt53 mutant mice (n=5-11) on a C57BL/6 background. 
Measurements were performed using a Sysmex haematology analyser. 1-way ANOVA 
followed by unpaired 2-tailed Student’s t test with Bonferroni correction for multiple 
comparisons. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Supplemental Figure 4. (A,B) Ultrastructure of platelets from cases 2-II-3, 2-III-5 and 
2-III-7 carrying the variant showing the presence of large platelets with numerous 
vacuoles indicating increased fragility, contrasting the normal discoid platelet appearance 
in 2-III-6 unaffected family member. (A) Overview. (B) Detail. Bars, 1 µm.  
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Supplemental Figure 5. (A) Flow cytometric measurement of α-granule release (P-
selectin-FITC antibody) in Tpm4+/+ (black), Tpm4Plt53/+ (blue) and Tpm4Plt53/Plt53 (light 
blue) platelets after activation with the depicted agonists (n=4, representative of three 
independent experiments). (B) Thrombus formation of whole, anti-coagulated blood from 
Tpm4+/+ and Tpm4Plt53/Plt53 mice on collagen under flow (shear rate 1000s-1). 
Representative bright field (left) and fluorescence images (right). Bar, 50 µm. (C) Tail 
bleeding times in bone marrow chimeric Tpm4+/+ and Tpm4Plt53/Plt53 mice. Each dot 
represents an individual. Unpaired 2-tailed Student’s t test, *P < 0.05. 
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Supplemental Figure 6. (A) Investigation of TPM4 (yellow) and F-actin (red) 
localization in fetal liver cell-derived Tpm4Plt53/Plt53 megakaryocytes by confocal 
immunofluorescence microscopy showing that TPM4 is not detectable. Bar, 20 µm. (B) 
Investigation of the localization of TPM4 (yellow), tubulin (green) and F-actin (red) in 
mature Tpm4+/+ fetal liver cell-derived megakaryocytes at the start of proplatelet 
formation by confocal immunofluorescence microscopy. Bar, 20 µm.  
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Supplemental Figure 7. (A) Knockdown of TPM4 expression by shRNA in human 
CD34+ derived megakaryocytes. Evaluation of megakaryocyte maturation at day 8 and 
day 10 of culture by CD41/CD42 surface staining is shown (n=5). (B) Normal ploidy of 
Tpm4+/Plt53 and Tpm4Plt53/Plt53 megakaryocytes. Whole bone marrow was incubated with 
propidium iodide and CD41-FITC antibody and ploidy of CD41-positive cells was 
determined by flow cytometry (n=5). (C) Examination of proplatelet tip size of cultured 
fetal liver derived Tpm4+/+, and Tpm4Plt53/Plt53 megakaryocytes. Each dot represents a 
proplatelet tip. Results are pooled from two independent experiments. Mann Whitney 
test, ***P < 0.001. 
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Supplemental Figure 8. Decreased F-actin content relative to the platelet size in non-
stimulated and thrombin-stimulated Tpm4Plt53/+ (blue) and Tpm4Plt53/Plt53 (light blue) 
compared to Tpm4+/+ (black) platelets (n=4). 1-way ANOVA followed by unpaired 2-
tailed Student’s t test with Bonferroni correction. *P < 0.05; **P < 0.01; ***P < 0.001. 
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Supplemental Figure 9. Investigation of Tropomodulin 3 (TMOD3, green), F-actin (red) 
and Tubulin (grey) localisation in fetal liver cell-derived Tpm4+/+ (A) and Tpm4Plt53/Plt53 
(B) megakaryocytes by confocal immunofluorescence microscopy. Overview: Bar, 20 
µm. Detail: Bar, 10 µm.  
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Supplemental Figure 10. (A) Investigation of potential cytoskeletal regulators affected 
in Tpm4Plt53/+and Tpm4Plt53/Plt53 platelets (left) and fetal liver cell-derived megakaryocytes 
(right) by Western blot. Blots are representative of 2-3 individual experiments. β-actin 
was used as loading control. (B) Investigation of the localization of NMM-IIa (green) and 
F-actin (red) in Tpm4+/+ and Tpm4Plt53/Plt53 fetal liver cell-derived megakaryocytes by 
confocal immunofluorescence microscopy. Bar, 20 µm. 
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